Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02465567 · ClinicalTrials.gov registry record · Phase 3
Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects With Moderate to Very Severe COPD (Ethos)
A Phase 3 study, sponsored by Pearl Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 8,588
- Enrollment target
NCT02465567: Completed Phase 3 study, sponsored by Pearl Therapeutics.
NCT02465567 is a Phase 3 study that has completed, run by Pearl Therapeutics. The registered enrollment target is 8,588 participants, above the 771-participant average among 15,282 other Phase 3 trials with a reported enrollment target (1014% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02465567, a Phase 3 study, has completed, sponsored by Pearl Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 8,588 participants
- Enrollment target
Study Summary
This is a randomized, double-blind, multi-center, parallel-group study to assess the efficacy and safety of PT010 relative to PT003 and PT009 on COPD exacerbations subjects with moderate to very severe COPD.
Primary Outcome
Adjusted Rate of Moderate or Severe Exacerbations
Interventions
- DRUG BGF MDI 320/14.4/9.6 μg
- DRUG GFF MDI 14.4/9.6 μg
- DRUG BFF MDI 320/9.6 μg
- DRUG BGF MDI 160/14.4/9.6 μg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8,588 participants |
| Start Date | 2015-06-30 |
| Est. Completion | 2019-07-26 |
| Phase | Phase 3 |
What the finished NCT02465567 record still lists
NCT02465567 is an interventional study that assigns participants to a tested intervention. Its 8,588 participants enrollment target places it among the larger protocols in the corpus, above the 771-participant average among 15,282 other Phase 3 trials with a reported enrollment target (1014% higher).
The record links to 0 conditions, and to 4 interventions - of which BGF MDI 320/14.4/9.6 μg is the first listed.
NCT02465567 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02465567 about?
NCT02465567 is a clinical study titled "Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects With Moderate to Very Severe COPD (Ethos)". This is a randomized, double-blind, multi-center, parallel-group study to assess the efficacy and safety of PT010 relative to PT003 and PT009 on COPD exacerbations subjects with moderate to very severe COPD.
What is the current status of trial NCT02465567?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 8,588 participants. The study started on 2015-06-30. Estimated completion is 2019-07-26.
What interventions are being tested in trial NCT02465567?
The interventions under investigation include: BGF MDI 320/14.4/9.6 μg (DRUG), GFF MDI 14.4/9.6 μg (DRUG), BFF MDI 320/9.6 μg (DRUG), BGF MDI 160/14.4/9.6 μg (DRUG).
Who is sponsoring clinical trial NCT02465567?
This trial is sponsored by Pearl Therapeutics, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02465567's enrollment target sits among peer trials
8,588 32nd of 2000 higher than 1,969 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06098079 · 8,600 participants · Phase 4
Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE)
- NCT06058234 · 8,680 participants
Medicare Anti-Aβ mAb Coverage With Evidence Development (CED) Study
- NCT05336877 · 8,744 participants
Aveir VR Coverage With Evidence Development Post-Approval Study
- NCT07185828 · 8,286 participants · NA
Informing Low-acuity Emergency Department Patients of Non-emergent Resources (2)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI